When the federal government wants to set medical policy and testing standards, it assembles a panel of experts to analyze the state of that particular medical art and make recommendations to the FDA. You would hope—and expect—that the process would be strictly analytical and scientific, uncontaminated by outside commercial interests.

In at least one recent case, you would be wrong.